This finding prompted the authors to propose the inclusion of RERE in the genes to be tested in individuals who fulfill the diagnostic criteria for CHARGE syndrome but do not carry pathogenic variants in CHD7 [42]. This evidence concerns the gene RERE and CHARGE syndrome.